Results 231 to 240 of about 369,993 (297)

ABT-263, a BCL-2 inhibitor, selectively eliminates latently HIV-1-infected cells without viral reactivation. [PDF]

PLoS One
Kang JE, Seo HW, Kim DE, Shin YH, Bae S, Yoon CH.   +5 more
europepmc   +1 more source

Apoptosis and Bcl-2 oncoprotein expression in the human fetal central nervous system [PDF]

, 1998
Wai‐Yee Chan, David T. Yew
openalex   +1 more source

Enhanced Blood‐Brain Barrier Penetrability of BACE1 SiRNA‐Loaded Prussian Blue Nanocomplexes for Alzheimer's Disease Synergy Therapy

Exploration, EarlyView.
BACE1 interfering RNA, metallothionein and ruthenium complexes ([Ru(bpy)2dppz]2+) were all loaded in prussian blue nanoparticles (PRM‐siRNA). PRM‐siRNA under near‐infrared light irradiation showed good photothermal effect and triggered instantaneous opening of blood‐brain barrier for enhanced drug delivery.
Xiaoyuan Ding, Yanyu Hu, Xiaotong Feng, Zekun Wang, Qile Song, Chunxue Dai, Bangjia Yang, Xiaoyan Fu, Dongdong Sun, Cundong Fan   +9 more
wiley   +1 more source

Synthesis and Biological Evaluation of Quercetagetin Derivatives as the Inhibitors of Mcl-1 and Bcl-2 Against Leukemia. [PDF]

Int J Mol Sci
Li K, Ge X, Liu W, Huang L, Lv X, Tang Y, He Z, Yang Y, Chen M, Zeng J, Cheng P.   +10 more
europepmc   +1 more source

Identification of a novel regulatory domain in Bcl-xL and Bcl-2

, 1997
Brian S. Chang, Andy J. Minn, Steven W. Muchmore, Stephen W. Fesik, Craig B. Thompson   +4 more
openalex   +1 more source

Innovative PDK1‐Degrading PROTACs Transform Cancer Aerobic Glycolysis and Induce Immunogenic Cell Death in Breast Cancer

Exploration, EarlyView.
In this study, A04, a compound targeting the degradation of metabolic enzyme PDK1, was developed by PROTAC technology, which significantly inhibited tumor proliferation by disrupting the Warburg effect in cancer cells. In the mouse model, A04 could prolong postoperative survival, and also remodel the immunosuppressive microenvironment, which could ...
Aohua Deng, Renming Fan, Jiakui Gou, Ruoxi Sang, Ruizhuo Lin, Ting Zhao, Junyan Zhuang, Yongrui Hai, Jialin Sun, Gaofei Wei   +9 more
wiley   +1 more source

Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer

, 1995
Gabriella Fontanini, S. Vignati, D Bigini, A Mussi, Marco Lucchi, C. A. Angeletti, Fulvio Basolo, Generoso Bevilacqua   +7 more
openalex   +1 more source

Emerging Target Discovery Strategies Drive the Decoding of Therapeutic Power of Natural Products and Further Drug Development: A Case Study of Celastrol

Exploration, EarlyView.
Using celastrol as a case study, this review summarizes various target discovery strategies for natural products, including chemical proteomics, protein microarray, degradation‐based protein profiling, proteome‐wide label‐free approaches, network pharmacology, target‐based drug screening, and indirect strategies.
Yanbei Tu, Guiyu Dai, Yanyan Chen, Lihua Tan, Hanqing Liu, Meiwan Chen   +5 more
wiley   +1 more source

Deciphering the effects of bixin on pulmonary alveolar adenocarcinoma migration and proliferation via targeting BAX/BCL-2 and Cyclin D1. [PDF]

Sci Rep
Varghese R, Ramamoorthy S.
europepmc   +1 more source

Bcl-2/E1B 19 kDa-interacting protein 3-like protein (Bnip3L) interacts with Bcl-2/Bcl-xL and induces apoptosis by altering mitochondrial membrane permeability

, 1999
Tetsuo Imazu, Shigeomi Shimizu, Shinji Tagami, Mieko Matsushima, Yusuke Nakamura, Tsuneharu Miki, Äkïhïko Okuyama, Yoshihide Tsujimoto   +7 more
openalex   +1 more source